Select a community
All Communities
Home > Community Treatment Reports > AVP-923 (DM/Q) Treatment Report
What is AVP-923 (DM/Q)?

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis and Multiple Sclerosis Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell 		# of patients evaluated by
Emotional lability 3 1
Other 1 0

See all 3 patients currently taking AVP-923 (DM/Q)

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 100%
None
0 0%

Most commonly reported side effects

headache
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  30 mg daily 60 mg daily 80 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking AVP-923 (DM/Q) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe
1 100% Side effects too severe: 100%

See all 1 patient who’ve stopped taking AVP-923 (DM/Q)

Duration See details about how long patients take this treatment ▼

Currently Taking AVP-923 (DM/Q)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking AVP-923 (DM/Q)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
1 100%
$25-49
0 0%
< $25
0 0%

Report created on March 21, 2010.